Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will take steps to (a) increase diagnostic capacity at memory clinics, (b) prepare primary care, (c) increase numbers of specialists capable of prescribing new medicines, (d) adopt new diagnostic technology including blood biomarkers, (e) ensure adequate CT scanning capacity and (f) raise awareness among patients of new medications for Alzheimer's Disease.

The Government is committed to transforming diagnostic services and will support the National Health Service to increase diagnostic capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging and computed tomography scanners.

Our Elective Reform Plan, published in January 2025, builds on the investments already made with an ambitious vision for the future of diagnostic testing. This will include more straight-to-test pathways, increasing and expanding Community Diagnostic Centres (CDCs), and better use of technology. With 170 CDCs due to be up and running by the end of March 2025, CDCs can take on more of the growing diagnostic demand within elective care. We will also deliver additional CDC capacity in 2025/26 by expanding a number of existing CDCs and building up to five new ones.

Alongside Alzheimer’s Research UK, the Alzheimer’s Society, Gates Ventures, and the People’s Postcode Lottery, the National Institute for Health Research is funding the Blood Biomarker Challenge, which seeks to produce the clinical and economic data that could make the case for the use of a blood test in the NHS to support the diagnosis of dementia.

New disease modifying drugs for Alzheimer’s disease are in development. NHS England is working closely with system partners to ensure that arrangements are in place to support the adoption of any new licensed and National Institute for Health and Care Excellence-recommended treatments as soon as possible.